Show simple item record

dc.contributor.authorJonker, D J
dc.contributor.authorRosen, L S
dc.contributor.authorSawyer, M B
dc.contributor.authorde Braud, F
dc.contributor.authorWilding, G
dc.contributor.authorSweeney, C J
dc.contributor.authorJayson, Gordon C
dc.contributor.authorMcArthur, G A
dc.contributor.authorRustin, G
dc.contributor.authorGoss, G
dc.contributor.authorKantor, J
dc.contributor.authorVelasquez, L
dc.contributor.authorSyed, S
dc.contributor.authorMokliatchouk, O
dc.contributor.authorFeltquate, D M
dc.contributor.authorKollia, G
dc.contributor.authorNuyten, D S A
dc.contributor.authorGalbraith, S
dc.date.accessioned2012-06-27T09:11:56Z
dc.date.available2012-06-27T09:11:56Z
dc.date.issued2011-06
dc.identifier.citationA phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. 2011, 22 (6):1413-9 Ann Oncolen_GB
dc.identifier.issn1569-8041
dc.identifier.pmid21131369
dc.identifier.doi10.1093/annonc/mdq599
dc.identifier.urihttp://hdl.handle.net/10541/230943
dc.description.abstractThis study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in patients with advanced/metastatic solid tumors.
dc.language.isoenen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMOen_GB
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAlanine
dc.subject.meshAngiogenesis Inhibitors
dc.subject.meshAntineoplastic Agents
dc.subject.meshDose-Response Relationship, Drug
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMaximum Tolerated Dose
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Metastasis
dc.subject.meshNeoplasms
dc.subject.meshNeovascularization, Pathologic
dc.subject.meshReceptors, Fibroblast Growth Factor
dc.subject.meshReceptors, Vascular Endothelial Growth Factor
dc.subject.meshTriazines
dc.titleA phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.en
dc.typeArticleen
dc.contributor.departmentDivision of Medical Oncology, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Canada.en_GB
dc.identifier.journalAnnals of Oncologyen_GB
html.description.abstractThis study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in patients with advanced/metastatic solid tumors.


This item appears in the following Collection(s)

Show simple item record